NCT05822284View on ClinicalTrials.gov

ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
Non-small Cell Lung Cancer
Interventions
DIAGNOSTIC_TEST

NGS and ctDNA-MRD detection

NGS and ctDNA-MRD detection

Trial Locations (1)

410011

Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, China, Changsha

All Listed Sponsors
collaborator

Geneplus-Beijing Co. Ltd.

INDUSTRY

lead

Second Xiangya Hospital of Central South University

OTHER

NCT05822284 - ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy | Biotech Hunter | Biotech Hunter